Markets:

Overview

News

Currencies

International

Treasuries

Merck & Co (NY:MRK)

122.26 +0.40 (+0.33%)

Official Closing Price Updated: 4:10 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients ↗

December 13, 2024

Bicycle Therapeutics presented data on zelenectide pevedotin, highlighting enhanced efficacy in cancer patients with NECTIN4 gene amplification.

Via Benzinga

These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over ↗

December 12, 2024

Via The Motley Fool

Topics Stocks

NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases. ↗

December 12, 2024

Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued.

Via Chartmill

AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients ↗

December 11, 2024

AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results in ovarian cancer.

Via Benzinga

Merck & Co Unusual Options Activity For December 02 ↗

December 02, 2024

Via Benzinga

Why NYSE:MRK provides a good dividend, while having solid fundamentals. ↗

November 25, 2024

Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).

Via Chartmill

10 Health Care Stocks With Whale Alerts In Today's Session ↗

December 10, 2024

Via Benzinga

Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer ↗

December 09, 2024

Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg.

Via Benzinga

2 Healthcare Dividend Stocks to Hold for the Long Haul ↗

December 07, 2024

Via The Motley Fool

Why Summit Therapeutics Stock Rocketed 6% Higher on Friday ↗

December 06, 2024

Via The Motley Fool

This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy? ↗

December 05, 2024

Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable.

Via The Motley Fool

3 Ultra-Cheap Dividend Stocks to Buy in December ↗

December 05, 2024

Via The Motley Fool

Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance ↗

December 03, 2024

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.

Via Benzinga

The Smartest Dividend Stocks to Buy With $3,000 Right Now ↗

November 28, 2024

They may not offer the very highest yields, but their dividends are built to last, and even grow.

Via The Motley Fool

The Data Shows Three Market-Jolting Forces On The Move ↗

November 27, 2024

What we saw in the inflation data, income and spending-related reports points to a couple of big moves we need to start making now.

Via Talk Markets

Topics Economy Stocks / Equities

Why Is Merck Stock Trading Higher On Monday? ↗

November 25, 2024

Merck's ZENITH trial shows Winrevair significantly lowers morbidity or mortality risk in PAH patients, building on earlier Phase 3 STELLAR results.

Via Benzinga

Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns ↗

November 21, 2024

Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer.

Via Benzinga

2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist ↗

November 21, 2024

Via The Motley Fool

NYSE:MRK appears to be flying under the radar despite its strong fundamentals. ↗

November 21, 2024

In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals.

Via Chartmill

Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients ↗

November 19, 2024

Merck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals.

Via Benzinga

Not-So-Big Pharma ↗

November 16, 2024

Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration.

Via Talk Markets

Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth ↗

November 15, 2024

To gain an edge, this is what you need to know today.

Via Benzinga

European And US Vaccine Stocks Are Under Pressure - Here's WHy ↗

November 15, 2024

Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts.

Via Benzinga

Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial ↗

November 14, 2024

Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy.

Via Benzinga

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics ↗

November 14, 2024

Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China.

Via Investor's Business Daily

Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day? ↗

November 14, 2024

Stocks in these "safe" sectors are selling off as investors gravitate toward growth.

Via The Motley Fool

Topics ETFs Stocks

10 Health Care Stocks With Whale Alerts In Today's Session ↗

November 13, 2024

Via Benzinga

Biotech Stocks Are Rallying: What Is Your Playbook? ↗

November 11, 2024

If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.

Via Talk Markets

3 Stocks Poised for a Breakout ↗

November 09, 2024

All 3 stocks are high on my watchlist.

Via The Motley Fool

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Merck & Co (NY:MRK)

Headline News about Merck & Co

Starting at $3.75/week.

Subscribe Today